Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P45.01 - Therapeutic effectiveness of Lorlatinib After Alectinib in Japanese Patients With ALK-Positive NSCLC in Real-World
00:00 - 00:00 | Presenter: Yasushi Goto
- Abstract
Loading... -
+
P45.02 - Molecular Profile of Resistance Mutations Post Multiple Lines of Tyrosine Kinase Inhibitors in ALK-Positive Non-Small-Cell Lung Cancer
00:00 - 00:00 | Presenter: Moushumi Suryavanshi
- Abstract
Loading... -
+
P45.03 - Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy
00:00 - 00:00 | Presenter: Enriqueta Felip
- Abstract
Loading... -
+
P45.04 - Phase II Study of Brigatinib in ROS1 Positive Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated with Crizotinib: Barossa Cohort 2
00:00 - 00:00 | Presenter: Jun Sakakibara-Konishi
- Abstract
Loading... -
+
P45.05 - Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival
00:00 - 00:00 | Presenter: Sally CM Lau
- Abstract
Loading... -
+
P45.06 - Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer
00:00 - 00:00 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
P45.07 - Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK+ NSCLC
00:00 - 00:00 | Presenter: Sabine Schmid
- Abstract
Loading... -
+
P45.08 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading... -
+
P45.09 - Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada
00:00 - 00:00 | Presenter: Simren Chotai
- Abstract
Loading... -
+
P45.10 - Effects of ALK Tyrosine Kinase Inhibitors in the Treatment of Metastatic NSCLC: A Systematic Review and Meta-Analysis
00:00 - 00:00 | Presenter: Michela Febbraro
- Abstract
Loading... -
+
P45.11 - Co-occurring CDKN2A/B Alteration Is Associated With Worse Survival Outcomes in Advanced ALK-Positive Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Oscar Arrieta
- Abstract
Loading... -
+
P45.12 - Renal Function Change During Alectinib in ALK Rearranged Non-Small Cell Lung Cancer: A Retrospective Multicentre Analysis
00:00 - 00:00 | Presenter: Chiara Paratore
- Abstract
Loading... -
+
P45.13 - Efficacy and Safety of Crizotinib in Real-World ROS1-rearranged NSCLC: A Retrospective Canadian Cohort
00:00 - 00:00
- Abstract
Loading... -
+
P45.14 - Real-World Experience on Treatment of crizotinib in ALK/ROS1/MET Alterated Non-Small-Cell Lung Cancer Patients in China
00:00 - 00:00 | Presenter: Shaoyu Yang
- Abstract
Loading... -
+
P45.15 - Clinical Outcomes, Long-Term Survival and Toleration With Sequential Therapy of First-Line Crizotinib Followed by Alectinib in ALK+ NSCLC
00:00 - 00:00 | Presenter: Zihua Zou
- Abstract
Loading... -
+
P45.16 - Adverse Event Burden of Oral Tyrosine Kinase Inhibitors in EGFR and ALK Metastatic Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: David Riley
- Abstract
Loading... -
+
P45.17 - Outcomes of Patients on ALK Inhibitor Therapy in NHS Tayside Scotland UK
00:00 - 00:00 | Presenter: Sherie George
- Abstract
Loading... -
+
P45.18 - NSCLC Patients With ALK Gene Rearrangement – Croatian Experience
00:00 - 00:00 | Presenter: Marko Jakopović
- Abstract
Loading...